These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30710906)

  • 1. Appearance of lentigines in psoriasis patient treated with guselkumab.
    Lee EB; Reynolds KA; Pithadia DJ; Wu JJ
    Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
    Gutiérrez-González E; Batalla A; de la Mano D
    Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept.
    Costa LA; Belinchón I; Betlloch I; Pérez-Crespo M; Mataix J
    Dermatol Online J; 2008 Jan; 14(1):11. PubMed ID: 18319028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab.
    Santos-Juanes J; Coto P; Mallo S; Galache C; Sánchez del Río J; Torre JC
    Dermatology; 2008; 216(3):279. PubMed ID: 18216489
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple lentigines confined to a resolving psoriatic plaque.
    Martí N; Molina I; López V; Terradez L; Jordá E
    Dermatol Online J; 2009 Oct; 15(10):15. PubMed ID: 19951633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab-induced multiple lentigines in areas of resolved psoriatic plaques: A case report and literature review.
    Zhang S; Liang J; Tian X; Zhou X; Liu W; Chen X; Zhang X
    Dermatol Ther; 2021 Sep; 34(5):e15048. PubMed ID: 34212464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentigines in previous psoriatic plaques in a patient treated with infliximab.
    Bardazzi F; Magnano M; Antonucci VA; Balestri R; Sgubbi P; Patrizi A
    Eur J Dermatol; 2012; 22(5):698-9. PubMed ID: 22940696
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast.
    Vazquez B; Gonzalez V; Molina I; Montesinos E; Ramon MD; Monteagudo C
    Clin Exp Dermatol; 2019 Jan; 44(1):66-67. PubMed ID: 29926507
    [No Abstract]   [Full Text] [Related]  

  • 10. Lentigines in psoriatic plaques: are they unique?
    Dawn G; McHenry P; Burden AD
    Clin Exp Dermatol; 2001 Jul; 26(5):459. PubMed ID: 11488842
    [No Abstract]   [Full Text] [Related]  

  • 11. Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'.
    McCarthy S; Heffron CCBB; Murphy M
    Clin Exp Dermatol; 2019 Apr; 44(3):358-359. PubMed ID: 30575106
    [No Abstract]   [Full Text] [Related]  

  • 12. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentigines in resolving psoriatic plaques: rarely reported sequelae in pediatric cases.
    LaRosa CL; Foulke GT; Feigenbaum DF; Cordoro KM; Zaenglein AL
    Pediatr Dermatol; 2015; 32(3):e114-7. PubMed ID: 25727728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple lentigines confined to psoriatic plaques.
    Burrows NP; Handfield-Jones S; Monk BE; Sabroe RA; Geraghty JM; Norris PG
    Clin Exp Dermatol; 1994 Sep; 19(5):380-2. PubMed ID: 7955492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple lentigines confined to a resolving psoriatic plaque, treated without phototherapy.
    Rogers M
    Clin Exp Dermatol; 1995 Sep; 20(5):446. PubMed ID: 8593731
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety evaluation of guselkumab for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
    Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple lentigines confined to psoriatic plaques induced by biologic agents in psoriasis therapy: a case and review of the literature.
    Dogan S; Atakan N
    Cutan Ocul Toxicol; 2015; 34(3):262-4. PubMed ID: 25806714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
    Nawas Z; Hatch M; Ramos E; Liu M; Tong Y; Peranteau A; Tyring S
    Skin Therapy Lett; 2017 Mar; 22(2):8-10. PubMed ID: 28329405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple lentigines clearing in resolving psoriatic plaques.
    Mahendran R; Norris PG
    Clin Exp Dermatol; 1999 May; 24(3):237. PubMed ID: 10354187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.